HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 Trial.

AbstractBACKGROUND:
Ranolazine, a piperazine derivative with anti-ischemic effects, reduces the frequency of angina and improves exercise performance in patients with chronic angina. The effects of ranolazine in patients with established ischemic heart disease and chronic angina undergoing percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) is not well described. We hypothesized that ranolazine would reduce ischemic events, regardless of revascularization.
METHODS:
We examined the 1-year incidence of recurrent cardiovascular (CV) events in the subgroup of patients with prior chronic angina (n = 3565) enrolled in the randomized, double-blind, placebo-controlled Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation ACS (MERLIN)-Thrombolysis In Myocardial Infarction (TIMI) 36 trial who did or did not have a PCI within 30 days of the index event.
RESULTS:
Ranolazine reduced the risk of recurrent ischemia following admission regardless of whether patients had (hazard ratio [HR], 0.69; 95% confidence interval [CI] 0.51-0.92] or did not have PCI (HR, 0.81; 95% CI, 0.66-0.99; P interaction = 0.39). CV death, myocardial infarction, and recurrent ischemia were similarly lower with ranolazine in the PCI group (HR, 0.71; 95% CI, 0.55-0.91) vs the non-PCI group (HR, 0.91; 95% CI, 0.78-1.06; P interaction = 0.10), with a nominally significant decrease in CV death (HR, 0.39; 95% CI, 0.16-0.93) in the PCI group vs no difference in the non-PCI group (HR, 1.19; 95% CI, 0.89-1.59; P interaction = 0.02).
CONCLUSIONS:
In patients with chronic angina, ranolazine reduced recurrent ischemic events, regardless of whether patients did or did not receive PCI within 30 days of a non-ST-segment ACS.
AuthorsJorge A Gutierrez, Ewa Karwatowska-Prokopczuk, Sabina A Murphy, Luiz Belardinelli, Ramin Farzaneh-Far, Gennyne Walker, David A Morrow, Benjamin M Scirica
JournalClinical cardiology (Clin Cardiol) Vol. 38 Issue 8 Pg. 469-75 (Aug 2015) ISSN: 1932-8737 [Electronic] United States
PMID26059896 (Publication Type: Journal Article, Randomized Controlled Trial)
Copyright© 2015 Wiley Periodicals, Inc.
Chemical References
  • Sodium Channel Blockers
  • Ranolazine
Topics
  • Acute Coronary Syndrome (drug therapy, surgery)
  • Aged
  • Angina Pectoris (drug therapy)
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Percutaneous Coronary Intervention (methods)
  • Ranolazine (therapeutic use)
  • Recurrence
  • Sodium Channel Blockers (therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: